Amgen After ASCO: Questions Remain On Lumakras, Bemarituzumab
Executive Summary
Remaining questions after ASCO include whether Lumakras (sotorasib) might work in first-line NSCLC with certain co-mutations and if ocular toxicities will hamper bemarituzumab in gastric cancer.